Polyploidy spectrum: a new marker in HCC classification.
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ genetics
Carcinoma, Hepatocellular
/ genetics
Case-Control Studies
Cell Differentiation
/ genetics
Cell Nucleus
/ pathology
Cell Proliferation
/ genetics
Cell Transformation, Neoplastic
/ genetics
Female
Hepatocytes
/ pathology
Humans
Liver Neoplasms
/ genetics
Male
Middle Aged
Polyploidy
Prognosis
Young Adult
cell cycle
hepatocellular carcinoma
histopathology
liver
molecular pathology
Journal
Gut
ISSN: 1468-3288
Titre abrégé: Gut
Pays: England
ID NLM: 2985108R
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
29
11
2018
revised:
25
02
2019
accepted:
24
03
2019
pubmed:
14
4
2019
medline:
30
1
2020
entrez:
14
4
2019
Statut:
ppublish
Résumé
Polyploidy is a fascinating characteristic of liver parenchyma. Hepatocyte polyploidy depends on the DNA content of each nucleus (nuclear ploidy) and the number of nuclei per cell (cellular ploidy). Which role can be assigned to polyploidy during human hepatocellular carcinoma (HCC) development is still an open question. Here, we investigated whether a specific ploidy spectrum is associated with clinical and molecular features of HCC. Ploidy spectra were determined on surgically resected tissues from patients with HCC as well as healthy control tissues. To define ploidy profiles, a quantitative and qualitative in situ imaging approach was used on paraffin tissue liver sections. We first demonstrated that polyploid hepatocytes are the major components of human liver parenchyma, polyploidy being mainly cellular (binuclear hepatocytes). Across liver lobules, polyploid hepatocytes do not exhibit a specific zonation pattern. During liver tumorigenesis, cellular ploidy is drastically reduced; binuclear polyploid hepatocytes are barely present in HCC tumours. Remarkably, nuclear ploidy is specifically amplified in HCC tumours. In fact, nuclear ploidy is amplified in HCCs harbouring a low degree of differentiation and Our results underline the importance of quantification of cellular and nuclear ploidy spectra during HCC tumorigenesis.
Identifiants
pubmed: 30979717
pii: gutjnl-2018-318021
doi: 10.1136/gutjnl-2018-318021
pmc: PMC6984053
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
355-364Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Nature. 2005 Oct 13;437(7061):1043-7
pubmed: 16222300
Am J Pathol. 2014 Feb;184(2):322-31
pubmed: 24140012
Hepatology. 2019 Mar;69(3):1242-1258
pubmed: 30244478
Hepatology. 1996 Aug;24(2):289-93
pubmed: 8690394
J Cell Sci. 2007 Oct 15;120(Pt 20):3633-9
pubmed: 17895361
Gastroenterology. 2018 Apr;154(5):1421-1434
pubmed: 29274368
J Clin Invest. 2015 Mar 2;125(3):981-92
pubmed: 25621497
Nat Genet. 2013 Oct;45(10):1134-40
pubmed: 24071852
Semin Cell Dev Biol. 2013 Apr;24(4):347-56
pubmed: 23333793
J Natl Cancer Inst. 1988 Nov 16;80(18):1480-5
pubmed: 2846856
Nat Rev Mol Cell Biol. 2004 Jan;5(1):45-54
pubmed: 14708009
Hepatology. 2016 Aug;64(2):599-615
pubmed: 27016325
Front Oncol. 2014 May 26;4:123
pubmed: 24904834
Dev Cell. 2006 Jun;10(6):759-70
pubmed: 16740478
Pharmacol Ther. 1992;53(3):275-354
pubmed: 1409850
Gastroenterology. 2018 Oct;155(4):1233-1249.e22
pubmed: 30009820
N Engl J Med. 2017 Jun 1;376(22):2109-2121
pubmed: 28445112
Mol Oncol. 2011 Aug;5(4):315-23
pubmed: 21852209
Cell. 2007 Nov 2;131(3):452-62
pubmed: 17981114
Development. 2013 Jan 1;140(1):3-12
pubmed: 23222436
J Hepatol. 2017 Oct;67(4):727-738
pubmed: 28532995
Clin Res Hepatol Gastroenterol. 2012 Feb;36(1):29-34
pubmed: 21778131
Br J Cancer. 1989 Feb;59(2):198-205
pubmed: 2930686
Virchows Arch B Cell Pathol Incl Mol Pathol. 1993;64(6):387-93
pubmed: 8148960
Gastroenterology. 2018 Apr;154(5):1229-1231
pubmed: 29510129
Annu Rev Cell Dev Biol. 2011;27:585-610
pubmed: 21801013
Cancer Cell. 2012 Jun 12;21(6):765-76
pubmed: 22698402
J Biol Chem. 2003 May 23;278(21):19095-101
pubmed: 12626502
Cell Tissue Res. 2017 May;368(2):405-410
pubmed: 27301446
Semin Cancer Biol. 2000 Jun;10(3):161-71
pubmed: 10936066
J Clin Invest. 2009 Jul;119(7):1880-7
pubmed: 19603546
J Hepatol. 2012 Apr;56(4):984-6
pubmed: 22008737
Gastroenterology. 2015 Oct;149(5):1226-1239.e4
pubmed: 26099527
Gut. 2005 Feb;54(2):297-302
pubmed: 15647198
Trends Cell Biol. 2013 Nov;23(11):556-66
pubmed: 23849927
Curr Opin Genet Dev. 2007 Apr;17(2):157-62
pubmed: 17324569
Adv Exp Med Biol. 2010;676:123-35
pubmed: 20687473
Dev Cell. 2018 Nov 5;47(3):390
pubmed: 30399338
Cancer. 1994 Jan 15;73(2):281-8
pubmed: 8293389
Nat Genet. 2015 May;47(5):505-511
pubmed: 25822088
Curr Biol. 2012 Jul 10;22(13):1166-75
pubmed: 22658593
Elife. 2015 Dec 27;4:
pubmed: 26673893
Clin Cancer Res. 2017 Aug 1;23(15):4364-4375
pubmed: 28246274
Oncotarget. 2015 Apr 20;6(11):8430-1
pubmed: 25940698
Curr Biol. 2014 Mar 17;24(6):598-608
pubmed: 24613310
Gastroenterology. 1993 Nov;105(5):1449-54
pubmed: 8224647